Advertisement

Ergot alkaloids and the modulation of hypothalamic function

  • E. Flückiger

Abstract

Central nervous system actions of ergot alkaloids in connection with ergot poisoning have been known for centuries, but well into the present century these effects were only considered to be signs of toxicity. Barger’s classic treatise on The Alkaloids of Ergot (1938) reviews the early descriptions of central effects, while a review edited by Berde and Schild (1978) covers the more recent literature on ergot pharmacology.

Keywords

Growth Hormone Growth Hormone Secretion Ergot Alkaloid Acromegalic Patient Prolactin Secretion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arakelian, M. C. and Libertun, C. (1977). H1 and 112 histamine receptor participation in the brain control of prolactin secretion in lactating rats. Endocrinology, 100, 890–895PubMedCrossRefGoogle Scholar
  2. Bach, N. J., Hall, D. A. and Kornfeld, E. D. (1974). Descarboxylysergic acid (9, 10-didehydro 6-methylergoline). J. Med. Chem., 17, 312–313PubMedCrossRefGoogle Scholar
  3. Baker, B. I. (1976). Ability of various factors to oppose the stimulatory effect of dibutyryl cyclic AMP on the release of melanocyte-stimulating hormone by the rat pituitary in vitro. J. Endocr., 68, 283–287PubMedCrossRefGoogle Scholar
  4. Barger, G. (1938). The alkaloid of ergot. In Handb. Exp. Pharma. Ergänzungswerk, 6, Springer, Berlin, 84–822Google Scholar
  5. Benker, G., Hackenberg, K., Hamburger, B. and Reinwein, D. (1976). Effects of growth hormone release-inhibiting hormone and bromocryptine (CB 154) in a state of abnormal pituitary-adrenal function. Clin. Endocr., 5, 187–190PubMedCrossRefGoogle Scholar
  6. Berde, B. and Schild, H. 0. (1978). Ergot Alkaloids and Related Compounds. Handbook of Experimental Pharmacology, Springer Verlag, HeidelbergCrossRefGoogle Scholar
  7. Bisset, G. W. (1968). The milk-ejection reflex and the actions of oxytocin, vasopressin and synthetic analogues on the mammary gland. In B. Berde (ed.). Neurohypophyseal Hormones and Similar Polypeptides, Handbook of Experimental Pharmacology (New Series), Vol. 23, Springer Verlag, Berlin, Heidelberg and New YorkGoogle Scholar
  8. Bivens, C. H., Lebovitz, H. E. and Feldman, J. M. (1973). Inhibition of hypoglycaemia-induced growth hormone secretion by the serotonin antagonist cyproheptadine and methysergide. N. Engt J. Med., 289, 236–239CrossRefGoogle Scholar
  9. Borrell, J., Piva, F. and Martini, L. (1976). Adrenergic and cholinergic inputs to the amygdala. In F. Labrie, J. Meites and G. Pelletier (eds.). Hypothalamus and Endocrine Function, Plenum Press, New York, London, 37CrossRefGoogle Scholar
  10. Brown, P. S. (1967). The effect of 5-hydroxytryptamine and two of its antagonists on ovulation in the mouse. J. Endocr., 37, 327–333PubMedCrossRefGoogle Scholar
  11. Burden, J. L., Hillhouse, E. W. and Jones, M. T. (1974). A proposed model of the neurotransmitters involved in the control of corticotrophin releasing hormone. J. Endocr., 63, 20P - 21 PPubMedGoogle Scholar
  12. Camanni, F., Massara, F., Fassio, V. and Molinatti, G. M. (1975). Changes in plasma growth hormone levels in normal and acromegalic subjects following administration of 2-bromo-a-ergo-cryptine. J. Clin. Endocr. Metab., 40, 363–366PubMedCrossRefGoogle Scholar
  13. Cameron E. H. D. and Scarisbrick, J. J. (1973). Determination of corticosterone in rat plasma by competitive protein-binding assay and its use in assessing the effects of CB154 and perphenazine on adrenal function. J. Endocr., 58, xxvii-xxviiiGoogle Scholar
  14. Caron, M. G., Drouin, J., Raymond, V., Kelly, P. A. and Labrie, F. (1976). Specificity of the catecholaminergic effect on prolactin secretion and (3H) dihydroergocryptine binding. Clin. Res., 24, 656AGoogle Scholar
  15. Cavagnini, F., Raggi, U., Micossi, P., Di Landro, A. and Invitti, C. (1976). Effect of an antiserotoninergic drug, metergoline, on the ACTH and cortisol response to insulin hypoglycaemia and lysine-vasopressine in man. J. Clin. Endocr. Metab., 43, 306–312PubMedCrossRefGoogle Scholar
  16. Cerletti, A. (1959). Discussion contribution. Neuropsychopharmacology, 1, 117–123Google Scholar
  17. Cerletti, A. and Doepfner, W. (1958). Comparative study on the serotonin antagonism of amide derivatives of lysergic acid and of ergot alkaloids. J. PharmacoL Exp. Ther., 122, 124–136PubMedGoogle Scholar
  18. Chen, H. J. and Meites, J. V. (1975). Effects of biogenic amines and TRH on release of prolactin and TSH in the rat. Endocrinology, 96, 10–14PubMedCrossRefGoogle Scholar
  19. Chiodini, P. G., Liuzzi, A., Müller, E. E., Botalla, L., Cremascoli, G., Oppizzi, G., Verde, G. and Silvestrini, F. (1976). Inhibitory effect of an ergoline derivative, methergoline, on growth hormone and prolactin levels in acromegalic patients. J. Clin. Endocr. Metab., 43, 356–363PubMedCrossRefGoogle Scholar
  20. Clarke, G. and Lincoln, D. W. (1977). Effects of catecholamine antagonists on the milk-ejection reflex of the anaesthetized rat. Brit. J. PharmacoL, 59, 458P - 459 PGoogle Scholar
  21. Clemens, J. A. (1976). Neuropharmacological aspects of the neural control of prolactin secretion. In F. Labrie, J. Meites and G. Pelletier (eds.). Hypothalamus and Endocrine Function, Plenum Press, New York and London, 283CrossRefGoogle Scholar
  22. Clemens, J. A., Sawyer, B. D. and Cerimele, B. (1977). Further evidence that serotonin is a neurotransmitter involved in the control of prolactin secretion. Endocrinology, 100, 692–698PubMedCrossRefGoogle Scholar
  23. Clemens, J. A., Shaar, C. J., Tandy, W. A. and Roush, M. E. (1971). Effects of hypothalamic stimulation on prolactin secretion in steroid-treated rats. Endocrinology, 89, 1317 1320Google Scholar
  24. Clemens, J. A., Smalstig, E. B. and Shaar, C. J. (1975). Inhibition of prolactin secretion by lergotrile mesylate: mechanism of action. Acta endocr. (Kbh), 79, 230–237Google Scholar
  25. Corrodi, H., Farnebo, L. O., Fuxe, K. and Hamberger, B. (1975). Effect of ergot drugs on central 5-hydroxytryptamine neurones: evidence for 5-hydroxytryptamine release or 5-hydroxytryptamine receptor stimulation. Eur. J. PharmacoL, 30, 172–181PubMedCrossRefGoogle Scholar
  26. Corrodi, H., Fuxe, K., Hökfelt, T., Lidbrink, P. and Ungerstedt, U. (1973). Effect of ergot drugs on central catecholamine neurones: evidence for a stimulation of central dopamine neurones. J. Pharm. Pharmac., 25, 409–411CrossRefGoogle Scholar
  27. Curzon, G. (1975). CSF homovanillic acid: an index of dopaminergic activity. Advan. Neurot., 9, 349–357Google Scholar
  28. Dammacco, F., Rigillo, N., Tafaro, E., Gagliardi, F., Chetri, G. and Dammacco, A. (1976). Effects of 2-bromo- -ergocryptine and pimozide on growth hormone secretion in man. Hormone. Metab. Res., 8, 247–248CrossRefGoogle Scholar
  29. Dang, B. T. and Voogt, J. L. (1977). Termination of pseudopregnancy following hypothalamic implantation of prolactin. Endocrinology, 100, 873PubMedCrossRefGoogle Scholar
  30. Davies, C., Jacobi, J., Lloyd, H. M. and Meares, J. D. (1974). DNA synthesis and the secretion of prolactin and growth hormone by the pituitary gland of the male rat: effects of diethylstilboestrol and 2-bromo-a-ergocryptine methanesulphonate. J. Endocr., 61, 411–417PubMedCrossRefGoogle Scholar
  31. Del Pozo, E., Darragh, A., Lancranjan, I., Ebeling, D., Burmeister, P., Bühler, F., Marbach, P. and Braun, P. (1977b). Effect of bromocriptine on the endocrine system and foetal development. Clin. Endocr., 6, Suppl. 47s–55sGoogle Scholar
  32. Del Pozo, E., Goldstein, M., Friesen, H., Brun Del Re, E. and Eppenberger, U. (1975). Lack of action of prolactin suppression on the regulation of the human menstrual cycle. Am. J. Obstet. Gynec., 123, 719–723PubMedGoogle Scholar
  33. Del Pozo, E. and Lancranjan, I. (1978). Clinical use of drugs modifying the release of anterior pituitary hormones. In W. F. Ganong and L. Martini (eds.). Frontiers in Neuroendocrinology, Vol. 5, Raven Press, New York, 207–247Google Scholar
  34. Del Pozo, E., Lancranjan, I., Clarenbach, P. and Wirz, A. (1977a). The role of serotonin in the release of prolactin: a methodological appraisal. Acta endocr., (Kbh), 85, 54 (Suppl. 212)Google Scholar
  35. Donoso, A. O., Bishop, W., Fawcett, C. P., Krulich, L. and McCann, S. M. (1971). Effects of drugs that modify brain monoamine concentrations on plasma gonadotrophin and prolactin levels in the rat. Endocrinology, 89, 774–784PubMedCrossRefGoogle Scholar
  36. Drouva, S. V. and Gallo, R. V. (1977). Further evidence for inhibition of episodic luteinizing hormone release in ovariectomized rats by stimulation of dopamine receptors. Endocrinology, 100, 702–798CrossRefGoogle Scholar
  37. Ectors, F., Danguy, A. and Pasteels, J. L. (1972). Ultrastructure of organ cultures of rat hypophyses exposed to ergocornine. J. Endocr., 52, 211–212PubMedCrossRefGoogle Scholar
  38. Everett, J. W. (1964). Central neural control of reproductive functions of the adenohypophysis. Physiol. Rev., 44, 373–431PubMedGoogle Scholar
  39. Feldman, J. M., Plonk, J. W. and Bivens, C. H. (1976). Inhibitory effect of serotonin antagonists on growth hormone release in acromegalic patients. Clin. Endocr., 5, 71–78PubMedCrossRefGoogle Scholar
  40. Flückiger, E. and Del Pozo, E. (1978). Influence on the endocrine system. In B. Berde and H. O. Schild (eds.). Ergot Alkaloids and Related Compounds. Handbook of Experimental Pharmacology, Springer Verlag, Heidelberg, 615–690CrossRefGoogle Scholar
  41. Flückiger, E., Marko, M., Doepfner, W. and Niederer, W. (1976). Effects of ergot alkaloids on the hypothalamo-pituitary axis. Postgrad. Med. J., (Suppl. 1 ) 52, 57–61Google Scholar
  42. Fuxe, K., Agnati, L. and Everitt, B. (1975a). Effect of methergoline on central monoamine neurons. Evidence for a selective blockade of central 5-HT receptors. Neuroscience Letts., 1, 283–290CrossRefGoogle Scholar
  43. Fuxe, K. and Hökfelt, T. (1970). Central monoaminergic systems and hypothalamic function. In L. Martini, M. Motta and F. Fraschini (eds.). The Hypothalamus, Academic Press, New York, 123–138Google Scholar
  44. Fuxe, K., Löfstrum, A., Agnati, L. F., Everitt, B. J., Hökfelt, T., Jonsson, G. and Wiesel, F. A. (1975b). On the role of central catecholamine and 5-hydroxytryptamine neurons in neuroendocrine regulation. In W. E. Stumpf and L. D. Grand (eds.), Karger, Basel, 420Google Scholar
  45. Fuxe, K., Löfström, A., Agnati, L. F., Everitt, B. J., Johansson, O., Jonsson, G., Wuttke, W. and Goldstein, M. (1976). Role of monoamines in the control of gonadotrophin secretion. In T. C. A. Kumar (ed.). Neuroendocrine Regulation of Fertility, International Symposium, Simla, 1974, Karger, Basel, 124–140Google Scholar
  46. Githens, T. S. (1917). The influence of ergotoxine on body temperature. J. Pharmac. Exp. Ther., 10, 327–340Google Scholar
  47. Gräf, K. J., Neumann, F. and Horowski, R. (1976). Effect of the ergot derivative lisuride hydrogen maleate on serum prolactin concentrations in female rats. Endocrinology, 98, 598–605PubMedCrossRefGoogle Scholar
  48. Greibrokk, T., Currie, B. L., Johansson, K. N. G., Hansen, J. J., Folkers, K. and Bowers, C. Y. (1974). Purification of a prolactin inhibiting hormone and the revealing of hormone d-GHIH which inhibits the release of growth hormone. Biochem. Biophys. Res. Commun., 59, 704–709PubMedCrossRefGoogle Scholar
  49. Grosvenor, C. E. (1956). Effect of ergotamine on milk-ejection in lactating rats. Proc. Soc. Exp. BioL Med., 91, 294–296PubMedCrossRefGoogle Scholar
  50. Grosvenor, C. E. and Turner, C. W. (1956). Ergotamine oxytocin and milk let-down in lactating rats. Proc. Soc. Exp. Biol. Med., 93, 466–468PubMedCrossRefGoogle Scholar
  51. Grosvenor, C. E. and Turner, C. W. (1957). Evidence for adrenergic and cholinergic components in milk let-down reflex in lactating rats. Proc. Soc. Exp. BioL Med., 95, 719–722PubMedCrossRefGoogle Scholar
  52. Haigler, H. J. and Aghajanian, G. K. (1974). Peripheral serotonin antagonists: failure to antagonize serotonin in brain areas receiving a prominent serotoninergic input. J. Neural Transm., 35, 257–273CrossRefGoogle Scholar
  53. Hamilton, J. M., Flaks, A., Saluja, P. G. and Maguire, S. (1975). Hormonally induced renal neoplasia in the male Syrian hamster and the inhibitory effect of 2-bromo-a-ergocryptine methane-sulfonate. J. Natn. Cancer Inst., 54, 1385–1400Google Scholar
  54. Harrower, A. D. B., Yap, P. L., Nairn, J. M., Walton, H. Y. and Craig, A. (1977). Growth hormone, insulin and prolactin secretion in anorexia nervosa and obesity during bromocriptine treatment. Br. Med. J., II, 156–159Google Scholar
  55. Hart, I. C. (1973). Effect of 2-Br-a-ergocryptine on milk yield and the level of prolactin and growth hormone in the blood of the goat at milking. J. Endocr., 57, 179–180PubMedCrossRefGoogle Scholar
  56. Hery, M., Laplante, E. and Kordon, C. (1975). Role of pituitary sensitivity and adrenal secretion in the effect of serotonin depletion on luteinising hormone regulation. J. Endocr., 67, 463–464PubMedCrossRefGoogle Scholar
  57. Hery, M., Laplante, E. and Kordon, C. (1976). Participation of serotonin in the phasic release of LH. Part I: Evidence from pharmacological experiments. Endocrinology, 99, 496–503PubMedCrossRefGoogle Scholar
  58. Hökfelt, T. and Fuxe, K. (1972a). On the morphology and the neuroendocrine role of the hypothalamic catecholamine neurons. In K. M. Knigge, D. E. Scott and A. Weindl (eds.). Brain-endocrine Interaction, Median Eminence: Structure and Function, Karger, Basel, 181–223Google Scholar
  59. Hökfelt, T. and Fuxe, K. (1972b). Effects of prolactin and ergot alkaloids on the tuberoinfundibular dopamine (DA) neurons. Neuroendocrinology, 9, 100–122PubMedCrossRefGoogle Scholar
  60. Horowski, R. and Gräf, K.-J. (1975). Prolactin secretion in rats under the influence of dif ferent agents acting on the dopaminergic system. Acta endocr. (Kbh.), Suppl. 199, 203Google Scholar
  61. Horowski, R., Neumann, F. and Graf, K.-J. (1975). Influence of apomorphine hydrochloride dibutyryl-apomorphine and lysenyl on plasma prolactin concentrations in the rat. J. Pharm. Pharmac., 27, 532–534CrossRefGoogle Scholar
  62. Horowski, R. and Wachtel, H. (1976). Direct dopaminergic action of lisuride hydrogen maleate, an ergot derivative, in mice. Eur. J. PharmacoL, 36, 373–376PubMedCrossRefGoogle Scholar
  63. Kann, G. and Denamur, R. (1974). Possible role of prolactin during the oestrous cycle and gestation in the ewe. J. Reprod. Fert., 39, 473–483CrossRefGoogle Scholar
  64. Kann, G. and Martinet, J. (1975). Prolactin levels and duration of post-partum anoestrus in lactating ewes. Nature, 257, 63–64PubMedCrossRefGoogle Scholar
  65. Kato, Y., Nakai, Y., Imura, H., Chihara, K. and Ohgo, S. (1974). Effect of 5-hydroxytryptophan (5-HTP) on plasma prolactin levels in man. J. Clin. Endocr. Metab., 38, 695–697PubMedCrossRefGoogle Scholar
  66. Kehr, W. (1977). Effect of lisuride and other ergot derivatives on monoaminergic mechanisms in rat brain. Eur. J. Pharmacol., 41, 261–273PubMedCrossRefGoogle Scholar
  67. Kiyoshi, M., Zoshio, O., Mitsuko, H., Kaichiro, I. and Yuichi, K., (1974). Inhibition of thyrotropin and prolactin secretion in primary hypothyroidism by 2-Br-a-ergocryptine. J. Clin. Endocr. Metab., 39, 391–394CrossRefGoogle Scholar
  68. Kordon, C. (1971). Blockade of ovulation in the immature rat by local microinjection of a-methyl-dopa into the arcuate region of the hypothalamus. Neuroendocrinology, 7, 202–209PubMedCrossRefGoogle Scholar
  69. Kordon, C., Blake, C. A., Terkel, J. and Sawyer, C. H. (1973/74). Participation of serotonin containing neurons in the suckling-induced rise in plasma prolactin levels in lactating rats. Neuroendocrinology, 13, 213–223Google Scholar
  70. Kordon, C., Hery, M. and Enjalbert, A. (1976). Neurotransmitters and control of pituitary function. In F. Labrie, J. Meites and G. Pelletier (eds.). Hypothalamus and Endocrine Function, Plenum Press, New York and London, 51CrossRefGoogle Scholar
  71. Kraicer, P. F. and Shelesnyak, M. C. (1968). Interruption of pregnancy, induction of ovulation and delayed pseudopregnancy following suppression of luteal function. Acta endocr. (Kbh.), 58, 251–260Google Scholar
  72. Kraicer, P. F. and Strauss, J. F. (1970). Ovulation block produced by an inhibitor of luteotrophin, ergocornine. Acta endocr. (Kbh.), 65, 698–706Google Scholar
  73. Krieger, D. T., Amorosa, L. and Linick. F. (1975). Cyproheptadine induced remission of Cushing’s disease. New Engl. J. Med., 293, 893–896PubMedCrossRefGoogle Scholar
  74. Krieger, D. T. and Luria, M. (1976). Effectiveness of cyproheptadine in decreasing plasma ACTH concentration in Nelson’s syndrome. J. Clin. Endocr. Metab., 43, 1179–1182PubMedCrossRefGoogle Scholar
  75. Lachelin, G. C. L., Leblanc, H. and Yen, S. S. C. (1977). The inhibitory effect of dopamine agonists on LH release in women. J. Clin. Endocr. Metab., 44, 728–732PubMedCrossRefGoogle Scholar
  76. Lamberts, S. W. J. and Birkenhäger, J. C. (1976). Effect of bromocriptine in pituitary-dependent Cushing’s syndrome. J. Endocr., 70, 315–316PubMedCrossRefGoogle Scholar
  77. Lawson, D. M. and Gala, R. R. (1975). The influence of adrenergic, dopaminergic, cholinergic and serotoninergic drugs on plasma protein levels in ovariectomized, oestrogen-treated rats. Endocrinology, 96, 313–318PubMedCrossRefGoogle Scholar
  78. Leblanc, H., Lachelin, G. C. L., Abu-Fadil, S. and Yen, S. S. C. (1976). Effects of dopamine infusion on pituitary hormone secretion in humans. J. Clin. Endocr. Metab., 43, 668–674PubMedCrossRefGoogle Scholar
  79. Lichtensteiger, W. and Keller, P. J. (1974). Tubero-infundibular dopamine neurones and the secretion of luteinizing hormone and prolactin: extrahypothalamic influences, interaction with cholinergic systems and the effect of urethane anesthesia. Brain Res., 74, 279–303PubMedCrossRefGoogle Scholar
  80. Liuzzi, A., Chiodini, P. G., Botalla, L., Cremascoli, G., Müller, E. E. and Silvestrini, F. (1974). Decreased plasma growth hormone (GH) levels in acromegalics following CB 154 (2-Br-a-ergocryptine) administration. J. Clin. Endocr. Metab., 38, 910–912PubMedCrossRefGoogle Scholar
  81. Loew, D. M., Vigouret, J. M. and Jaton, A. L. (1976). Neuropharmacological investigations with two ergot alkaloids, hydergine and bromocriptine. Postgrad. Med. J., 52. Suppl. 1, 40–46Google Scholar
  82. Lu, K. H., Koch, Y. and Meites, J. (1971). Direct inhibition by ergocornine of pituitary prolactin release. Endocrinology, 89, 229–233PubMedCrossRefGoogle Scholar
  83. Macindoe, J. H. and Turkington, R. W. (1973). Stimulation of human prolactin secretion by intravenous infusion of 1-tryptophan. J. Clin. Invest., 52, 1972–1978PubMedPubMedCentralCrossRefGoogle Scholar
  84. MacLeod, R. M. (1976). Regulation of prolactin secretion. In L. Martini and W. F. Ganong (eds.). Frontiers in Neuroendocrinology, Raven Press, New York, 169Google Scholar
  85. MacLeod, R. M. and Lehmeyer, J. E. (1972). Regulation of the synthesis and release of prolactin. In G. E. W. Wolstenholme and J. Knight (eds.). Lactogenic Hormones, Churchill Livingstone, Edinburgh and London, 53–82Google Scholar
  86. McCann, S. M. (1974). Regulation of secretion of follicle-stimulating hormone and luteinizing hormone. In E. Knobil and W. H. Sawyer (eds.). Handbook of Physiology, Section 7: Endocrinology, Vol. 4, The Pituitary Gland and its Neuroendocrine Control Part 2 American Physiological Society, Washington, DC, 489–518Google Scholar
  87. Marko, M. and Flückiger, E. (1974). Inhibition of spontaneous and induced ovulation in rats by nonsteroidal agents. Experientia, 30, 1174–1176PubMedCrossRefGoogle Scholar
  88. Massara, F., Camanni, F., Belforte, L. and Molinatti, G. M. (1976a). Dopamine-induced inhibition of prolactin and growth hormone secretion in acromegaly. Lancet, 1, 485PubMedCrossRefGoogle Scholar
  89. Massara, F., Camanni, F., Belforte, L. and Molinatti, G. M. (1976b). Dopamine and inhibition of prolactin and growth-hormone secretion. Lancet, I, 913Google Scholar
  90. Meites, J. (1973). Control of prolactin secretion in animals. In J. L. Pasteels and C. Robin (eds.). Human Prolactin, Excerpta Medica, Amsterdam, 105–118Google Scholar
  91. Meites, J., Simpkins, J., Bruni, J. and Advis, J. (1976). Role of biogenic amines in control of anterior pituitary hormones. Internat. Res. Commun. Syst. Med. Sci., 5, 1–7Google Scholar
  92. Mendelson, W. B., Jacobs, L. S., Reichman, J. D., Othmer, E., Cryer, P. E., Trivedi, B. and Daughaday, W. H. (1975). Methysergide. Suppression of sleep-related prolactin secretion and enhancement of sleep-related growth hormone secretion. J. Clin. Invest., 56, 690–697PubMedPubMedCentralCrossRefGoogle Scholar
  93. Müller-Schweinitzer, E. and Weidmann, H. (1978). Basic pharmacological properties. In B. Berde and H. O. Schild (eds.). Ergot Alkaloids and Related Compounds. Handbook of Experimental Pharmacology, Springer Verlag, Heidelberg, 87–232CrossRefGoogle Scholar
  94. Neill, J. D. (1974). Prolactin: its secretion and control. In E. Knobil and W. H. Sawyer (eds.). Handbook of Physiology Section 7: Endocrinology, Vol. 4. The Pituitary Gland and its Neuroendocrine Control Part 2 American Physiological Society, Washington DC, 469–488Google Scholar
  95. Niswender, G. D. (1974). Influence of 2-Br-a-ergocryptine on serum levels of prolactin and the oestrous cycle in sheep. Endocrinology, 94, 612–615 (1974)Google Scholar
  96. Nooter, K. and Zeilmaker, G. H. (1970). Effects of ergocornine and hypothalamic stimulation on ovulation in the rat. J. Endocr., 48, lxivGoogle Scholar
  97. Pasteels, J. L., Danguy, A., Frerotte, M. and Ectors, F. (1971). Inhibition de la sécrétion de prolactine par l’ergocornine et la 2-Br-a-ergocryptine: action directe sur l’hypophyse en culture. Annls. Endocr. (Paris), 32, 188–192Google Scholar
  98. Penny, R. J. and Thody, A. J. (1976). Preliminary studies on the control of a-melanocytestimulating hormone secretion in the rat. J. Endocr., 69, 2P - 3 PPubMedGoogle Scholar
  99. Peracchi, M., Lombroso, G. C., D’Alberton, A., Cammareri, G., Caccamo, A. and Crosignani, P. G. (1977). Antiserotonin drugs in the treatment of the amenorrhea-galactorrhea. syndrome. Acta endocr. (Kbh), 85, 54 (Suppl. 212)Google Scholar
  100. Piva, F., Sterescu, N., Zanisi, M. and Martini, L. (1969). Non-steroidal antifertility agents affecting brain mechanisms. Bull. Wld. Hlth. Org., 41, 275–288Google Scholar
  101. Poulain, P. and Carette, B. (1976). Actions of iontophoretically applied prolactin on septal and preoptic neurons in the guinea-pig. Brain Res., 116, 172–176PubMedCrossRefGoogle Scholar
  102. Raj, H. G. and Greep, R. O. (1973). Inhibition of ovulation and luteinizing hormone secretion in the cyclic rat by ergotamine tartrate. Proc. Soc. exp. Biol. Med., 144, 960–962PubMedCrossRefGoogle Scholar
  103. Ranta, T., Männistö, P. and Tuomisto, J. (1977). Evidence for dopaminergic control of thyrotrophin secretion in the rat. J. Endocr., 72, 329–335PubMedCrossRefGoogle Scholar
  104. Rose, J. C. and Ganong, W. F. (1976). Neurotransmitter regulation of pituitary secretion. In W. B. Essman and L. Valzelli.(eds.). Current Developments in Psychopharmacology, Vol. 3, Spectrum Publications Inc., New York, 86Google Scholar
  105. Rothlin, E., Cerletti, A., Konzett, H., Schalch, W. R. and Taeschler, M. (1956). Zentrale vegetative LSD-Effekte. Experientia, 12, 154–155PubMedCrossRefGoogle Scholar
  106. Rutschmann, J. and Stadler, P. (1978). Chemical background. In B. Berde and H. O. Schild (eds.). Ergot Alkaloids and Related Compounds. Handbook of Experimental Pharmacology, Springer Verlag, Heidelberg, 29–85CrossRefGoogle Scholar
  107. Schally, A. V., Redding, T. W., Arimura, A., Dupont, A. and Linthcum, G. L. (1977). Isolation of gamma-amino butyric acid from pig hypothalami and demonstration of its prolactin release inhibiting (PIF) activity in vivo and in vitro. Endocrinology, 100, 681–691PubMedCrossRefGoogle Scholar
  108. Schlientz, W., Brunner, R., Rüegger, A., Berde, B., Stürmer, E. and Hofmann, A. (1968). ß-Ergokryptin, ein nues Alkaloid der Ergotoxin-Gruppe. Pharm. Acta Helv., 43, 497–509PubMedGoogle Scholar
  109. Seki, M., Seki, K., Yoshihara, T., Watanabe, N., Okumura, T., Tajima, C., Huan, S.-Y. and Kuo, C.-C. (1974). Direct inhibition of pituitary LH secretion in rats by CB 154 (2-Br-a-ergocryptine). Endocrinology, 94, 911–914PubMedCrossRefGoogle Scholar
  110. Shelesnyak, M. C. (1954). Ergotoxine inhibition of deciduoma formation and its reversal by progesterone. Am. J. Physiol., 179, 301–304PubMedGoogle Scholar
  111. Shelesnyak, M. C. (1955). Disturbance of hormone balance in the female rat by a single injection of ergotoxine ethanesulfonate. Am. J. Physiol., 180, 47–49 (1955)Google Scholar
  112. Sinha, Y. N., Selby, F. W. and Vanderlaan, W. P. (1974). Effects of ergot drugs on prolactin and growth hormone secretion and on mammary nucleic acid content in C3H/Bi mice, J. Natn. Cancer Inst., 52, 189–191Google Scholar
  113. Smith, A. F. (1975). The effect of apomorphine and ergocryptine on the release of MSH by the Pars intermedia of Rana pipiens. Neuroendocrinology, 19, 363–376.PubMedCrossRefGoogle Scholar
  114. Smith, V. G., Beck, T. W., Convey, E. M. and Tucker, H. A. (1974). Bovine serum prolactin, growth hormone, cortisol and milk yield after ergocryptine. Neuroendocrinology, 15, 172–181PubMedCrossRefGoogle Scholar
  115. Smythe, G. A., Compton, P. J. and Lazarus, L. (1976). Serotoninergic control of human growth hormone secretion: the actions of L-dopa and 2-bromo-a-ergocryptine. In A. Pecile and E. E. Müller (eds.). Growth Hormone and Related Peptides, Excerpta Medica, Amsterdam, 222–235Google Scholar
  116. Snider, S. R., Hutt, CH., Stein, B. and Fahn, S. (1975). Increase in brain serotonin produced by bromocriptine. Neuroscience Letts., 1, 237–241CrossRefGoogle Scholar
  117. Stoll, W. A. and Hofmann, A. (1943). Die Alkaloide der Ergotoxingruppe: Ergocristin, Ergokryptin, Ergocornin (7. Mitteilung über Ergot-Alkaloide)..Hely. Chim. Acta, 26„ 1570–1601Google Scholar
  118. Takahara, J., Arimura, A. and Schally, A. V. (1974). Suppression of prolactin release by a purified porcine PIF preparation and catecholamines infused into a rat hypophyseal portal vessel. Endocrinology, 95, 462–465PubMedCrossRefGoogle Scholar
  119. Taleisnik, S., Celis, M. E. and Tomatis, M. E. (1973/74). Release of melanocyte stimulating hormone by several stimuli through the activation of a 5- hydroxytryptamine-mediated inhibitory neuronal mechanism. Neuroendocrinology, 13, 327–388Google Scholar
  120. Tashjian, A. H. and Hoyt, R. F. (1972). Transient control of organ-specific functions in pituitary cells in culture. In M. Sussman (ed.). Molecular Genetics and Developmental Biology, Prentice Hall Inc., Englewood Cliffs, N. J., 353–387Google Scholar
  121. Thorner, M. O., Chait, A., Aitken, M., Benker, G., Bloom, S. R., Mortimer, C. H., Sanders, P., Stuart Mason, A. and Besser, G. M. (1975). Bromocriptine treatment of acromegaly. Br Med. J., 1, 299–303PubMedPubMedCentralCrossRefGoogle Scholar
  122. Tilders, F. J. H., Mulder, A. H. and Smelik, P. G. (1975). On the presence of a MSH-release inhibiting system in the rat neurointermediate lobe. Neuroendocrinology, 18, 125–130PubMedCrossRefGoogle Scholar
  123. Tindal, J. S. (1974). Hypothalamic control of secretion and release of prolactin. J. Reprod. Fert., 39, 437–461CrossRefGoogle Scholar
  124. Tolis, G., Pinter, E. J. and Friesen, H. (1975). The acute effect of 2-bromo-a-ergocryptine (CB 154) on anterior pituitary hormones and free fatty acids in man. Int. J. Clin. Pharmacol., 12, 281–283Google Scholar
  125. Vale, W., Rivier, C., Brown, M., Chan, L., Ling, N. and Rivier, J. (1976). Application of adenohypophyseal cell cultures to neuroendocrine studies. In F. Labrie, J. Meites and G. Pelletier (eds.). Hypothalamus and Endocrine Function, Plenum Press, New York and London, 397CrossRefGoogle Scholar
  126. Verde, G., Oppizzi, G., Colussi, G., Cremascoli, G., Botalla, L., Müller, E. E., Silvestrini, F., Chiodini, P. G. and Liuzzi, A. (1976). Effect of dopamine infusion on plasma levels of growth hormone in normal subjects and in acromegalic patients. Clin. Endocr., 5, 419–423PubMedCrossRefGoogle Scholar
  127. Wilson, C. A. (1974). Hypothalamic amines and the release of gonadotrophins and other anterior pituitary hormones. In A. B. Simmonds (ed.). Advances in Drug Research, Vol. 8, Academic Press, London and New York, 120–204Google Scholar
  128. Wuttke, W., Cassell, E. and Meites, J. (1971). Effects of ergocornine on serum prolactin and LH, and on hypothalamic content of PIF and LRF. Endocrinology, 88, 737–741PubMedCrossRefGoogle Scholar
  129. Yanai, R. and Nagasawa, H. (1970). Effect of ergocornine and 2-Br-a-ergocryptine (CB 154) on the formation of mammary hyperplastic alveolar nodules and the pituitary prolactin levels in mice. Experientia, 26, 649–650PubMedCrossRefGoogle Scholar
  130. Zeilmaker, G. H. (1964). Experimentele Onderzoekingen over let eerste Stadium van de zwangerschap bij de Rat. Academisch Proefshrift, AmsterdamGoogle Scholar
  131. Zeilmaker, G. H. and Carlsen, R. A. (1962). Experimental studies on the effect of ergocornine methanesulfonate on the luteotrophic function of the rat pituitary gland. Acta. endocr. (Kbh), 41, 321–335Google Scholar

Copyright information

© B. Cox, I. D. Morris and A. H. Weston 1978

Authors and Affiliations

  • E. Flückiger
    • 1
  1. 1.Biological and Medical Research DivisionSandoz LtdBasleSwitzerland

Personalised recommendations